{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:48:13Z","timestamp":1794023293371,"version":"4.8.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Inappropriate calcitonin (CT) release, a major feature of medullary thyroid cancer (MTC), may occur in neuroendocrine tumors (NETs). The aims of this retrospective study were to assess i) the characteristics and prognosis of CT-producing NETs, and ii) the value of CT monitoring during follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All patients with NETs in whom serum CT was assayed between 2010 and 2012 were included. MTCs were excluded. Clinical, biological, and histological characteristics were studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Twenty-one (12%) of 176 patients in whom serum CT was systematically assayed had concentrations &gt;100\u200ang\/l, with tumours predominantly of bronchial or pancreatic origin (<jats:italic>P<\/jats:italic>&lt;0.0001), and of high grade (<jats:italic>P<\/jats:italic>=0.0006). Poor prognosis was linked to high CT levels, poor differentiation, and grade 3. In a total group of 24 patients with serum CT &gt;100\u200ang\/l, symptoms potentially attributable to CT were recorded in eight, with occasional overlap with the carcinoid syndrome among other secretory syndromes. Immunohistochemistry could be performed in six tumor specimens, CT being detected in five. In 11 patients with five or more successive CT assays, hormone levels were fairly well correlated with clinical courses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Serum CT levels may be raised in some patients with NETs, especially from foregut origin, and of high grade. The suggested value of CT monitoring during follow-up must be confirmed in further studies.<\/jats:p><\/jats:sec>","DOI":"10.1530\/eje-15-0917","type":"journal-article","created":{"date-parts":[[2015,12,16]],"date-time":"2015-12-16T02:26:08Z","timestamp":1450232768000},"page":"335-341","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":37,"title":["Neuroendocrine tumors producing calcitonin: characteristics, prognosis and potential interest of calcitonin monitoring during follow-up"],"prefix":"10.1093","volume":"174","author":[{"given":"C\u00e9cile","family":"Nozi\u00e8res","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Chardon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Borson-Chazot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Hervieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Chikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lombard-Bohas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2016012219283130000_174.3.335.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-012-0439-5"},{"key":"2016012219283130000_174.3.335.2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1590\/S1807-59322009000700015","article-title":"Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma","volume":"64","author":"Toledo","year":"2009","journal-title":"Clinics (Sao Paulo)"},{"key":"2016012219283130000_174.3.335.3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00006676-199805000-00014","article-title":"Calcitonin-secreting tumors of the pancreas: about six cases","volume":"16","author":"Fleury","year":"1998","journal-title":"Pancreas"},{"key":"2016012219283130000_174.3.335.4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ando.2010.05.001","article-title":"Hypercalcitonemia revealing a somatostatinoma","volume":"71","author":"Do Cao","year":"2010","journal-title":"Annales D'endocrinologie"},{"key":"2016012219283130000_174.3.335.5","doi-asserted-by":"publisher","DOI":"10.4065\/80.1.116"},{"key":"2016012219283130000_174.3.335.6","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/BF02482815","article-title":"Calcitonin-producing pancreatic somatostatinoma: report of a case","volume":"28","author":"Sugimoto","year":"1998","journal-title":"Surgery Today"},{"key":"2016012219283130000_174.3.335.7","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1056\/NEJM197811302992213","article-title":"Calcitonin secretion by a pancreatic somatostatinoma","volume":"299","author":"Galmiche","year":"1978","journal-title":"New England Journal of Medicine"},{"key":"2016012219283130000_174.3.335.8","first-page":"30","article-title":"Pancreatic islet cell carcinoma producing gastrin, ACTH, alpha-endorphin, somatostatin and calcitonin","volume":"74","author":"Asa","year":"1980","journal-title":"American Journal of Gastroenterology"},{"key":"2016012219283130000_174.3.335.9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/01.meg.0000230091.76168.f9","article-title":"Digestive calcitonin-secreting tumors of the foregut: comparison with non-calcitonin-secreting tumors","volume":"18","author":"Wuilmet","year":"2006","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"2016012219283130000_174.3.335.10","first-page":"226","article-title":"VIP and calcitonin-producing pancreatic neuroendocrine tumor with watery diarrhea: clinicopathological features and the effect of somatostatin analogue","volume":"13","author":"Kon","year":"2012","journal-title":"Journal of the Pancreas"},{"key":"2016012219283130000_174.3.335.11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/MPA.0b013e3182015f5d","article-title":"Calcitonin-secreting pancreatic endocrine tumors: systematic analysis of a rare tumor entity","volume":"40","author":"Schneider","year":"2011","journal-title":"Pancreas"},{"key":"2016012219283130000_174.3.335.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-006-0250-1"},{"key":"2016012219283130000_174.3.335.13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0792"},{"key":"2016012219283130000_174.3.335.14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3109\/0284186X.2011.562919","article-title":"Well-differentiated pancreatic islet cell carcinoma: is there reversibility in mTOR inhibitor resistance?","volume":"50","author":"Walter","year":"2011","journal-title":"Acta Oncologica"},{"key":"2016012219283130000_174.3.335.15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.revmed.2006.02.010","article-title":"How to interprete hypercalcitoninemia?","volume":"27","author":"Levy-Bohbot","year":"2006","journal-title":"La Revue de M\u00e9decine Interne"},{"key":"2016012219283130000_174.3.335.16","doi-asserted-by":"publisher","DOI":"10.1159\/000308170"},{"key":"2016012219283130000_174.3.335.17","first-page":"549","article-title":"Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma","volume":"23","author":"Vainas","year":"2004","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"2016012219283130000_174.3.335.18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/3\/335.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/3\/335.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:33:22Z","timestamp":1676392402000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/174\/3\/335\/6655508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":18,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.1530\/eje-15-0917","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]}}}